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Abstract: The role of immune suppression by regulatory T (Treg) cells in the maintenance of immune
homeostasis is well established. However, little is known about how Treg cell function is inhibited on
viral infection to allow the development of a protective immune response. As viral RNA is a crucial
mediator for activation of antiviral immunity, we examined the effects of immunostimulatory RNA and
infection with RNA viruses on Treg cell function. We show that synthetic RNA oligonucleotides potently
inhibit Treg cell-induced suppression in a sequence-dependent manner. This effect is entirely dependent
on TLR7 activation of APCs and subsequent IL-6 production. In addition, stimulation with the RNA
viruses encephalomyocarditis virus and Sendai virus that specifically activate the RNA-sensing helicases
melanoma differentiation-associated gene 5 (MDA-5) and retinoic acid-inducible gene I (RIG-I) also blocks
Treg cell function. Interestingly, this effect is seen even in the absence of APCs. Consistent with this, both
Treg and T effector cells express RIG-I and MDA-5. Using MDA-5–deficient mice, we demonstrate that
the loss of Treg cell function on infection with encephalomyocarditis virus is strictly dependent on MDA-5
expression by Treg cells. Thus, we show in this study for the first time that activation of a RIG-I–like
helicase on Treg cells blocks their suppressive function. Regulatory T (Treg) cells play a central role in the
suppression of immune reactions and in the prevention of autoimmune responses harmful to the host (1, 2).
In particular, Treg cells suppress the activation of naive T effector (Teff) cells by inhibiting TCR-triggered
proliferation and differentiation of these cells (3). In the early phase of microbial infection, the suppressive
effect of Treg cells must, however, be overcome to enable the generation of an efficient immune response
against invading pathogens (4–6). In recent years, it has been shown that several bacterial components
can block the suppressive function of Treg cells. Two distinct mechanisms have so far been described: first,
bacterial molecules, such as LPS or CpG DNA, can activate APCs to produce inflammatory cytokines
that render Teff cells resistant to suppression by Treg cells (7). Alternatively, Treg cells themselves can
be directly stimulated: targeting human Treg cells with CpG DNA or with the bacterial lipoprotein
Pam3Cys-SK4 abrogates their suppressive function even in the absence of APCs (8–10). The direct
action of bacterial components on Treg cells can, however, also have the opposite effect: activation of
Treg cells by flagellin enhances their suppressive function (11). Whereas the effect of bacterial ligands
on Treg cell suppression has been described, little is known about the regulation of Treg cell function
upon viral infection. Although Treg cells are capable of suppressing antiviral immunity (12), most viral
infections can be cleared through the induction of an efficient host immune response, demonstrating that
Treg cell suppression can be overcome. Viruses are recognized by the innate immune system through
host pattern-recognition receptors (13, 14), and several receptors recognizing molecular patterns present
within viral RNA have recently been described. Single-stranded RNA from influenza virus initiates
the secretion of type I IFN through activation of TLR7 within the endosome (15). In our laboratory,
we found that synthetic short RNA oligonucleotides potently activate TLR7 in a sequence-dependent
manner (16). Furthermore, we showed that modification of the RNA by phosphorothioate (PTO) linkage
of the backbone enhances TLR7 stimulation (17). Viral RNA can also be recognized by cytosolic RNA
sensors, the retinoic acid-inducible gene I (RIG-I)–like helicases (18). This family of structurally related
proteins includes RIG-I, melanoma differentiation-associated gene 5 (MDA-5) and LGP2. Many RNA
viruses, such as the measles virus, the rabies virus, the vesicular stomatitis virus, the Sendai virus, or
the encephalomyocarditis virus (EMCV) induce type I IFN through these receptors (19–22). We have
recently identified virally encoded 5￿-triphosphate RNA as the natural ligand for the RIG-I receptor (23),
whereas MDA-5 recognizes the synthetic long double-stranded RNA polyinosinic-polycytidylic acid [poly
(I:C)] on cytosolic delivery (22). Although the detection of viral RNA by pattern recognition receptors
leads to strong immune activation, little is known about the effect of RNA ligands on Treg cell-induced
immune suppression. We show in this study that RNA oligonucleotides block suppression by Treg cells
in a sequence-specific and TLR7-dependent manner through inflammatory cytokines produced by APC.
Infection with viruses known to stimulate the cytosolic RNA-sensing receptors RIG-I and MDA-5 blocked
Treg cell function in a direct, APC-independent manner. Indeed, we show that Treg cells express RIG-
I-like helicases, and activation of the MDA-5 receptor leads to an arrest of their suppressive function.
Thus, suppression can be overcome both indirectly by RNA oligonucleotides activating TLR7 on APC
and through direct activation of RIG-I–like helicases expressed by Treg cells.
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The role of immune suppression by regulatory T (Treg) cells in themaintenance of immune homeostasis is well established. However,
little is knownabout howTregcell function is inhibited onviral infection to allow thedevelopment of aprotective immune response.As
viralRNAisa crucialmediator foractivationof antiviral immunity,we examined the effects of immunostimulatoryRNAand infection
with RNAviruses on Treg cell function.We show that synthetic RNA oligonucleotides potently inhibit Treg cell-induced suppression
in a sequence-dependent manner. This effect is entirely dependent on TLR7 activation of APCs and subsequent IL-6 production. In
addition, stimulation with the RNAviruses encephalomyocarditis virus and Sendai virus that specifically activate the RNA-sensing
helicases melanoma differentiation-associated gene 5 (MDA-5) and retinoic acid-inducible gene I (RIG-I) also blocks Treg cell func-
tion. Interestingly, this effect is seen even in the absence ofAPCs.Consistentwith this, bothTreg andTeffector cells expressRIG-I and
MDA-5. Using MDA-5–deficient mice, we demonstrate that the loss of Treg cell function on infection with encephalomyocarditis
virus is strictly dependent onMDA-5 expression by Treg cells. Thus, we show in this study for the first time that activation of a RIG-
I–like helicase on Treg cells blocks their suppressive function. The Journal of Immunology, 2010, 184: 939–946.
R
egulatory T (Treg) cells play a central role in the sup-
pression of immune reactions and in the prevention of
autoimmune responses harmful to the host (1, 2). In par-
ticular, Treg cells suppress the activation of naive T effector (Teff)
cells by inhibiting TCR-triggered proliferation and differentiation
of these cells (3). In the early phase of microbial infection, the
suppressive effect of Treg cells must, however, be overcome to
enable the generation of an efficient immune response against in-
vading pathogens (4–6). In recent years, it has been shown that
several bacterial components can block the suppressive function of
Treg cells. Two distinct mechanisms have so far been described:
first, bacterial molecules, such as LPS or CpG DNA, can activate
APCs to produce inflammatory cytokines that render Teff cells re-
sistant to suppression by Treg cells (7). Alternatively, Treg cells
themselves can be directly stimulated: targeting human Treg cells
with CpG DNA or with the bacterial lipoprotein Pam3Cys-SK4
abrogates their suppressive function even in the absence of APCs
(8–10). The direct action of bacterial components on Treg cells can,
however, also have the opposite effect: activation of Treg cells by
flagellin enhances their suppressive function (11).
Whereas the effect of bacterial ligands on Treg cell suppression
has been described, little is known about the regulation of Treg cell
function upon viral infection. Although Treg cells are capable of
suppressing antiviral immunity (12), most viral infections can be
cleared through the induction of an efficient host immune re-
sponse, demonstrating that Treg cell suppression can be overcome.
Viruses are recognized by the innate immune system through host
pattern-recognition receptors (13, 14), and several receptors rec-
ognizing molecular patterns present within viral RNA have re-
cently been described. Single-stranded RNA from influenza virus
initiates the secretion of type I IFN through activation of TLR7
within the endosome (15). In our laboratory, we found that syn-
thetic short RNA oligonucleotides potently activate TLR7 in
a sequence-dependent manner (16). Furthermore, we showed that
modification of the RNA by phosphorothioate (PTO) linkage of
the backbone enhances TLR7 stimulation (17). Viral RNA can
also be recognized by cytosolic RNA sensors, the retinoic acid-
inducible gene I (RIG-I)–like helicases (18). This family of struc-
turally related proteins includes RIG-I, melanoma differentiation-
associated gene 5 (MDA-5) and LGP2. Many RNAviruses, such as
the measles virus, the rabies virus, the vesicular stomatitis virus, the
Sendai virus, or the encephalomyocarditis virus (EMCV) induce
type I IFN through these receptors (19–22). We have recently
identified virally encoded 59-triphosphate RNAas the natural ligand
for the RIG-I receptor (23), whereas MDA-5 recognizes the
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synthetic long double-stranded RNA polyinosinic-polycytidylic
acid [poly (I:C)] on cytosolic delivery (22).
Although the detection of viral RNA by pattern recognition
receptors leads to strong immune activation, little is known about
the effect of RNA ligands on Treg cell-induced immune sup-
pression. We show in this study that RNA oligonucleotides block
suppression by Treg cells in a sequence-specific and TLR7-
dependent manner through inflammatory cytokines produced by
APC. Infection with viruses known to stimulate the cytosolic RNA-
sensing receptors RIG-I and MDA-5 blocked Treg cell function in
a direct, APC-independent manner. Indeed, we show that Treg cells
express RIG-I-like helicases, and activation of the MDA-5 receptor
leads to an arrest of their suppressive function. Thus, suppression
can be overcome both indirectly by RNA oligonucleotides acti-
vating TLR7 on APC and through direct activation of RIG-I–like
helicases expressed by Treg cells.
Materials and Methods
Mice
Female BALB/c and C57BL/6 mice were purchased from Harlan-
Winkelmann (Borchen, Germany). Experiments were performed using
BALB/c mice unless indicated otherwise. TLR7-deficient mice were kindly
provided by Prof. S. Akira (Osaka University, Osaka, Japan). MDA-5–
deficient mice back-crossed to the C57BL/6 background and DEREG mice
expressing GFP under the control of the forkhead box P3 (FoxP3) pro-
motor were described previously (22, 24). Mice were at least 8 wk of age at
the onset of experiments. Animal studies were approved by the local
regulatory agency (Regierung von Oberbayern, Munich, Germany).
Reagents
The 20-mer RNA oligonucleotides 9.2dr (59-UGU CCU UCA AUG UCC
UUCAA-39) (16), 2.2 (59-GCAUGCGACCUCUGUUUGA-39) (25), Poly
A, and the 21-mer Poly U (26) in both the unmodified phosphodiester (PD)
and fully phosphorothioated forms were obtained from CureVac (Tu¨bingen,
Germany) or Metabion (Munich, Germany). Poly (I:C) was purchased from
Invivogen (Toulouse, France). The unmodified 2.2 triphosphate RNA (PPP-
59-GCAUGCGACCUCUGUUUGA-39) (25) was produced in single- and
double-strand forms by in vitro transcription in our laboratory (23). The
PTO-modified CpG oligodesoxyribonucleotide 1826 (59-TCC ATG ACG
TTC CTG ACG TT-39) was obtained from the Coley Pharmaceutical Group
(Langenfeld, Germany) and used at 3 mg/ml for cell stimulation. The syn-
thetic TLR7 ligand CL097 was purchased from Invivogen and was used at
0.2 mg/ml. Anti-CD3 beads were generated by incubating monoclonal
hamster anti-mouse CD3 Ab (clone 145-2C11) (BD Biosciences, Heidel-
berg, Germany) with tosyl-activated polystyrene beads (Invitrogen, Carls-
bad, CA) according to the manufacturer’s instructions.
Flow cytometry
For flow cytometric analysis, cells were stained with anti-mouse CD4-FITC,
CD25-PE,MHC-II-PE, CD11c-APC, CD69-FITC and isotype controls (BD
Biosciences, Heidelberg, Germany). FoxP3 and BrdU incorporation were
detectedusing theeBioscienceTregcell stainingkit (eBioscience, SanDiego,
CA). After incubation with Pacific Blue-labeled FoxP3 Ab, cells were fixed
with 1% paraformadehyde in PBS, incubated with DNAse I (0.05 mg/ml in
PBS; Sigma-Aldrich, Steinheim, Germany) and stained with anti–BrdU-
FITC Ab (Invitrogen). Analysis was performed using a FACSCanto II flow
cytometer (BD Biosciences) and FlowJo software (TreeStar, Ashland, OR).
Purification of T cell subsets and APCs
CD4+CD25+ Treg cells and CD4+CD25neg Teff cells were purified from
spleen by two-step magnetic cell sorting (Miltenyi Biotec, Bergisch
Gladbach, Germany). The remaining cells were used as APCs in pro-
liferation assays (7). CD11c+ dendritic cells (DCs) were isolated by
magnetic cell sorting and positive selection. Contamination by MHC-II+
APC in the purified T cell fractions was ,1.5% (Supplemental Fig. 1).
Proliferation assays
T cells were cultured in RPMI 1640 medium supplemented with 10% FCS,
penicillin, streptomycin, 2 mM glutamine, 2 mM sodium pyruvate, 2 mM
nonessential amino acids, and 0.0001% of 2-mercaptoethanol (complete
RPMI). Cultures were incubated in triplicate at 37˚C and 5% CO2 in flat-
bottom 96-well plates. CD4+CD25neg Teff cells (7.5 3 104 cells in 200
ml) were activated with anti-CD3 beads at a bead-to-cell ratio of 1:5 in
the presence of APC (2 3 104 cells), CD4+CD25+ Treg cells (5 3 104
cells, unless indicated otherwise) and the indicated ligand. T cell stim-
ulation in the absence of APCs was performed using microbeads coated
with anti-CD3 and anti-CD28 Ab (Invitrogen) (bead-to-cell ratio 1:75).
Cells were then cocultured for 60 h, and BrdU (Roche Diagnostics,
Mannheim, Germany) was added for the last 12 h of culture. BrdU in-
corporation was detected by a chemoluminescence-based assay according
to the manufacturer’s instructions (Roche Diagnostics) or by flow cy-
tometry. For selected experiments, conditioned medium (CM) was pro-
duced by stimulating splenocytes with the indicated ligand for 4 h,
followed by extensive washing and culture in fresh medium for an ad-
ditional 20 h before removal and transfer of the supernatant into sup-
pression assays. Where indicated, CM was preincubated with anti–IL-6
Ab (5 mg/ml; R&D Systems, Minneapolis, MN) for 4 h prior to use in
suppression assays.
Cell stimulation with RNA
For endosomal targeting of TLR7, cells were transfected with RNA (final
concentration of 2 mg/ml) complexed with N-[1-(2,3-dioleoyloxy) propyl]-
N,N,N-trimethylammonium methyl-sulfate (DOTAP; Roche Diagnostics)
according to the manufacturer’s instructions. Cytosolic targeting of RIG-I
and MDA-5 was achieved by adding 200 ng purified RNA oligonucleotides
previously complexed in 50 ml Opti-MEM medium (Invitrogen) containing
1% Lipofectamine 2000 (Invitrogen). For stimulation of TLR3, poly (I:C)
(5 mg/ml) was added directly to the culture.
Viral stimulation
EMCV was kindly provided by Dr. Anne Krug (Munich, Germany). Sendai
virus (Cantell strain) was purchased from Charles River Laboratories
(Wilmington, MA) (27). For stimulation with active virus, virus particles
were added to the cell culture at a final concentration of 2.5 MOI (EMCV)
and 0.5 MOI (Sendai Virus) for 2 h in serum-free medium and sub-
sequently removed by repeated washing.
Quantitative PCR analysis and RNA microarray
CD4+CD25+ and CD4+CD25neg T cells were isolated as described above.
Total RNA was extracted from cells using High Pure RNA Isolation Kit
(Roche Diagnostics) according to the manufacturer’s instructions. One
microgram of RNA was converted to cDNA using the Transcriptor High
Fidelity cDNA Synthesis Kit (Roche Diagnostics). Real-time PCR am-
plification was performed with the Light Cycler TaqMan Master (Roche
Diagnostics) on a LightCycler 2.0 instrument (Roche Diagnostics) together
with the Universal Probe Library System (Roche Diagnostics). Relative
gene expression is shown as a ratio of the expression level of the gene of
interest to that of hypoxanthine phosphoribosyltransferase RNA de-
termined in the same sample. The primers were obtained from Metabion
(Planegg, Germany). CD4+GFPFoxP3+ and CD4+GFPFoxP3neg cells were
isolated from DEREG mice by negative selection of CD4+ T cells (In-
vitrogen) and subsequent FACS sorting for GFP+ and GFPneg cells. Purity
was .99%. cRNA was prepared according to the Affymetrix Labeling
Protocol (Affymetrix, Santa Clara, CA), fragmented, and hybridized to
Affymetrix GeneChip Mouse Genome 430 (Affymetrix). The complete
microarray data set has been deposited in the GEO database at the National
Center for Biotechnology Information (accession number GSE2389; www.
ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE18387).
RNA uptake imaging by fluorescence microscopy
To detect intracellular RNA, cells were transfected with a 39-fluorescein–
labeled 9.2dr RNA (Metabion, Martinsried, Germany). After 1 h of culture,
cells were fixed with 4% paraformaldehyde on poly-L-lysine coated object
slides (Menzel, Braunschweig, Germany). The cell membrane and nucleus
were stained at room temperature using Alexa 647-labeled cholera toxin
(Invitrogen) and DAPI (Sigma-Aldrich) prior to embedding with Vectar-
shield mounting medium (Vector Laboratories, Peterborough, U.K.). Im-
ages were obtained by fluorescence microscopy (Axiovert 2000 Carl Zeiss,
Jena, Germany; 40-fold magnification) using Carl Zeiss Axiovision soft-
ware and processed with Adobe Photoshop (Adobe, San Jose, CA) for
adjustment of contrast and size.
Cytokine ELISA
IL-6 cytokine concentrations were determined by ELISA (BD OptEIA, BD
Biosciences).Detectionof IFN-awasperformedbyusinga ratanti-mouse IFN-a
monoclonal Ab (clone RMMA-1) as capture Ab followed by rabbit polyclonal
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anti-mouse IFN-a as detection Ab (both from PBL Biomedical Laboratories,
Piscataway, NJ). HRP-conjugated donkey anti-rabbit IgG Ab was added as
secondary reagent (The Jackson Laboratory, Bar Harbor, ME) and recombinant
mouse IFN-a (PBL Biomedical Laboratories) was used as standard.
Statistical analysis
All data are presented as mean. Error bars indicate SEM of n = 3. Analysis
of variance was performed as appropriate by ANOVA or unpaired Student t
test using the GraphPad Prism software (GraphPad, La Jolla, CA).
Results
Immunostimulatory RNA oligonucleotides block Treg cell-induced
immune suppression in a sequence-dependent manner
To investigate whether RNA-induced immune activation influences
Treg cell function, we examined a panel of RNA ligands targeting
innate immune receptors for their ability to block Treg cell-induced
suppression of Teff cell proliferation. We used the synthetic short
RNA oligonucleotides 9.2dr, 21U, and 2.2 (16, 25, 26) to stimulate
cocultures of CD4+CD25neg Teff cells and CD4+CD25+ Treg cells
in the presence of APC and anti-CD3 Ab. Transfection of these
RNAs activates innate immunity through TLR7 (16, 17). A PTO
modification of the RNA backbone was used to enhance the stability
and immunostimulatory capacity of these oligonucleotides (17, 28).
Strikingly, transfection of the cocultured cells with the three PTO-
modified sequences potently blocked Treg cell-induced suppression
(Fig. 1A andSupplemental Fig. 2A). This effectwas clearly sequence-
specific, as an RNA of the same length containing only adenine nu-
cleotides (PolyA) did not abolish Treg cell-induced suppression. The
same RNA sequences (9.2dr and 2.2) with an unmodified PD back-
bone also significantly inhibited Treg cell function in a sequence-
dependent manner. For all further experiments with synthetic RNA
oligonucleotides, the PTO form was used. To confirm that the re-
covery of proliferation induced by immunostimulatory RNA in the
coculture indeed resulted from sustained Teff cell proliferation, we
measured BrdU incorporation in this population by flow cytometry.
As expected, the Treg cell-induced decrease in the proportion of
BrdU+ CD4+FoxP3neg Teff cells was prevented by the addition of
immunostimulatory RNA (Fig. 1B).
FIGURE 1. Treg cell-mediated suppression of Teff cell proliferation is blocked by synthetic RNA oligonucleotides in a sequence-dependent manner. A
and B, CD4+CD25neg murine Teff cells (7.5 3 104) were stimulated with anti-CD3 Ab (no Ab; conditions without Ab) and cultured alone (Teff only) or
together with increasing numbers of CD4+CD25+ Treg cells (1, 2, 3, and 4 3 104) in the presence of APC. Cocultures were transfected with the synthetic
RNA oligonucleotides 9.2dr or PolyA containing a PTO-modified (PTO) or unmodified PD backbone, using DOTAP. A, Proliferation of the coculture was
measured on day 3 by the incorporation of BrdU using a chemoluminescence ELISA and is indicated as relative light units per second (rlu/s). Error bars
indicate SEM of n = 3. Comparison to culture with Teff cells alone: pp, 0.05; ppp, 0.01; pppp, 0.001; no asterisk, no significant suppression. p, 0.001
for no ligand versus 9.2dr PTO; p , 0.01 for 9.2dr PTO versus Poly A PTO; p, 0.001 for no ligand versus 9.2dr PD; p , 0.05 for 9.2dr PD versus Poly A
PD; no significant difference for 9.2dr PTO versus 9.2dr PD; all calculated for the highest Treg concentration. B, Proliferation of the coculture was measured
on day 3 by flow cytometry to determine BrdU incorporation into CD4+FoxP3neg cells. Histograms are shown for two different concentrations of Treg cells (2
and 4 3 104). C and D, Cocultures were transfected with either single-stranded (ss) or double-stranded (ds) triphosphate 2.2 RNA (3P-RNA) or poly (I:C)
(pIC) using lipofectamine (Lipo) as transfection agent. E, 2 3 105 splenocytes were cultured with the indicated ligands for 24 h before FACS analysis of
CD69 expression on CD11c+ DC. Error bars indicate SEM of n = 3. pp, 0.05; ppp, 0.01 for comparison with untreated cells. No asterisk, not significant.
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Transfection of RIG-I– and MDA-5–activating RNA does not
influence Treg cell-induced immune suppression
In contrast to synthetic RNA, viral RNA generally bears a tri-
phosphate group at the 59 end and can thus activate the cytosolic
RIG-I receptor, leading to activation of innate immunity (23, 29).
To test the ability of triphosphate RNA to block Treg cell-induced
suppression, we generated a 59-triphosphate 2.2 RNA and targeted
it to the cytosol of the cocultured cells by lipid transfection (25).
Interestingly, stimulation of the cocultures by either single-
stranded or double-stranded triphosphate RNA did not alter Treg
cell-induced suppression (Fig. 1C). To test whether targeting RNA
to the RIG-I–like helicase MDA-5 inhibits suppression of Teff
proliferation by Treg cells, we performed lipotransfection of the
cocultured cells with the MDA-5 ligand poly (I:C) (22). Again, we
observed no changes in Teff cell suppression (Fig. 1D). Targeting
TLR3 by the addition of untransfected poly (I:C) (30) also failed
to inhibit Treg cell-induced suppression (Supplemental Fig. 2B).
Stimulation of TLR9 with CpG DNA, however, completely ab-
rogated Treg cell suppression as described previously (4) (Sup-
plemental Fig. 2C). The immunostimulatory efficacy of the
different RNA ligands was confirmed by analysis of the early
activation marker CD69. CD69 expression on DCs was strongly
upregulated by all immunostimulatory RNAs used (Fig. 1E and
Supplemental Fig. 2D). In contrast, transfection of RNA without
immunostimulatory sequence motifs (Poly A) did not increase
CD69 levels. In summary, we observed a clear blockade of Treg
cell-induced suppression by targeting TLR7 with synthetic RNAs
containing immunostimulatory motifs. In contrast, no significant
effects on Treg cell function were seen on liposomal transfection
of ligands that stimulate RIG-I, MDA-5, or TLR3.
Synthetic RNA oligonucleotides abrogate Treg cell-induced
suppression through TLR7
To test whether the block of Treg cell-induced suppression by
synthetic RNA oligonucleotides indeed depended on TLR7, we
stimulated cocultures of Teff cells, Treg cells, and APCs, all from
TLR7-deficient mice, with the PTO-modified 9.2dr RNA. Here, in
contrast to wild-type mice, no recovery of proliferation was seen on
transfection with 9.2dr RNA, demonstrating that abrogation of Treg
cell-induced suppression by this ligand is TLR7-dependent (Fig.
2A). The small molecule CL097, an imidazoquinoline derivative
and synthetic agonist for TLR7 (31), also restored proliferation in
a TLR7-dependent manner. In contrast, the TLR9 agonist CpG led
to a strong recovery of proliferation in both wild-type and TLR7-
deficient mice.
We next examined the importance of the transfection reagent for
the immunostimulatory effect of TLR7-activating RNA. Because
recognition of RNA by TLR7 takes place in the endosome (15), we
selected DOTAP as the transfection reagent for its ability to de-
liver RNA to the endosomal compartment (32, 33). In contrast to
DOTAP, lipofectamine is particularly suitable for the delivery of
RNA to targets in the cytoplasm (23, 34). We show that trans-
fection of the 9.2dr RNAwith lipofectamine has no effect on Treg
cell-induced suppression (Fig. 2B). This indicates a requirement
for efficient endosomal delivery of RNA oligonucleotides to ab-
rogate Treg cell-induced suppression through TLR7.
Activation of TLR7 blocks Treg cell-induced suppression in vivo
To examine whether the in vivo activation of an RNA-sensing re-
ceptor can inhibit Treg cell function, mice were injected with the
TLR7 agonist CL097 or with CpG. Cells were collected from the
draining lymph nodes on day 3 after initial stimulation to measure
Treg cell function. Indeed, in contrast to untreatedmice, theTreg cell-
induced suppression was abrogated upon stimulation with CL097
as well as with CpG (Fig. 2C). Importantly, the fraction of FoxP3+
cells within the CD4+CD25+ cells remained constant after stimula-
tion with CL097 in vivo, indicating that the loss of suppression was
not due to reduced numbers of Treg cells (Supplemental Fig. 3).
Thus, activation of TLR7 can overcome Treg cell-induced sup-
pression in vivo.
Inhibition of Treg cell function through RNA oligonucleotides
is not due to direct targeting of Treg cells
To examine whether synthetic RNA oligonucleotides can modulate
Treg function by direct targeting of the TLR7 receptor on these
cells, we cocultured wild-type Treg cells with APC and Teff cells
from TLR7-deficient mice. Stimulation of these cocultured cells
with 9.2dr RNA did not block the suppressive effects of the Treg
cells, demonstrating the absence of a direct effect on Treg cells
(Fig. 3A). This could result from poor RNA delivery to the en-
dosomal compartment of the Treg cells. Indeed, targeting RNA to
the endosome or to the cytoplasm of T cells is challenging, and
lipofection-based approaches have been largely unsuccessful (35,
36). To evaluate the efficacy of RNA uptake into T cells and DCs,
we transfected these cells with FITC-labeled RNA oligonucleo-
tides followed by analysis with fluorescence microscopy. No RNA
uptake was seen in T cells, whereas DC were efficiently trans-
fected using either DOTAP or lipofectamine (Fig. 3B). Thus,
lipofection efficiently delivers RNA oligonucleotides to DC but
fails to target the endosome or the cytoplasm of T cells.
Abrogation of Treg cell-induced suppression by synthetic RNA
oligonucleotides is mediated by APC-secreted IL-6
To determine which cell type responds to 9.2dr RNA to block Treg
cell-induced suppression, we cocultured wild-type APC with
FIGURE 2. Activation of TLR7 is essential for the inhibition of Treg
cell function by synthetic RNA oligonucleotides and also inhibits Treg
cell-induced suppression in vivo. Teff cells were stimulated with anti-CD3
Ab and cultured alone or together with Treg cells in the presence of APC
as in Fig. 1. A, Cells derived from either TLR7-deficient or wild-type
C57BL/6 mice were stimulated with 9.2dr PTO RNA (transfected with
DOTAP), the TLR7 agonist CL097, or CpG. B, Wild-type cocultures were
transfected with 9.2dr RNA PTO using either DOTAP or lipofectamine.
Error bars indicate SEM of n = 3. pp , 0.05; ppp , 0.01 for comparison
with culture without ligands. C, BALB/c mice (n = 10) were treated with
daily antebrachial injections of CL097 or CpG (both 100 mg) for 3 d. Teff
cells, Treg cells, and APCs were then isolated from the draining brachial
and axillary lymph nodes of these mice and cocultured in the presence of
anti-CD3 as in Fig. 1. Error bars indicate SEM of n = 3. ppp , 0.01 for
comparison with culture from untreated mice.
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TLR7-deficient T cells (both Teff and Treg cells). Even in the
absence of TLR7 on T cells, both 9.2dr RNA and the synthetic
ligand CL097 completely blocked Treg cell-induced suppression
(Fig. 4A), indicating that the inhibition of Treg cell suppression by
synthetic RNA oligonucleotides is mediated by APC. To determine
whether the inhibition of Treg cell function is mediated by a sol-
uble factor produced by APC, we stimulated cocultures of Teff and
Treg cells with supernatant from 9.2dr RNA-activated APC. To
ensure the absence of the ligand from the supernatant, supernatants
were generated by stimulation of APC with RNA for 2 h, thorough
washing of the cells, and culture for another 12 h in fresh medium.
The resulting CM was sufficient to reverse Treg cell-induced
suppression (Fig. 4B). In contrast, addition of CM generated by
APC from TLR7-deficient mice did not lead to recovery of pro-
liferation (data not shown). As the proinflammatory cytokine IL-6
is essential for protection from Treg cell-induced suppression by
CpG and LPS (4), we tested whether blocking IL-6 in the 9.2dr
RNA CM would impact the reversal of Treg cell-induced sup-
pression. Indeed, neutralization of IL-6 completely prevented the
block of Treg suppression by RNA oligonucleotides (Fig. 4B). We
next assessed the efficacy of the RNA ligands to induce IL-6
production in splenic APC. Consistent with its capacity to block
Treg cell suppression, 9.2dr RNA induced the highest levels of IL-
6 (Fig. 4C). Interestingly, targeting RIG-I with 59-triphosphate
RNA did not lead to secretion of IL-6, although the proin-
flammatory cytokine IFN-a was clearly induced (Fig. 4C). The
absence of IL-6 production on stimulation with 59-triphosphate
RNA may thus explain its inability to block Treg cell function.
RNA viruses inhibit Treg cell function independently from APC
The RNA-sensing receptors MDA-5 and RIG-I can be specifically
activated by distinct viruses: EMCVexclusively activates MDA-5,
whereas the Sendai virus specifically stimulates RIG-I (22, 37). To
examine the effect of viral infection on Treg cell-mediated sup-
pression of Teff cell proliferation, we infected cocultures of Teff
and Treg cells with these viruses. Strikingly, both in the presence
and in the absence of APC, the suppression of proliferation by
Treg cells was blocked on viral infection (Fig. 5A, 5B). Inhibition
FIGURE 3. Inhibition of Treg cell function by RNA oligonucleotides is
not due to direct targeting of Treg cells. A, Wild-type (WT) C57BL/6 Treg
cells were cocultured with either TLR7-deficient or wild-type Teff cells
and APC in the presence of anti-CD3 as in Fig. 1A and stimulated with
9.2dr PTO RNA transfected with DOTAP. Error bars indicate SEM of n =
3. B, T cells and DC were purified from the spleen by magnetic sorting
prior to transfection with fluorescein-labeled (green) 9.2dr PTO RNA using
either DOTAP or lipofectamine. Two hours later, cells were fixed and
stained with Alexa 647-labeled cholera toxin (cell membrane dye, red) and
DAPI (nucleic dye, blue). Cells were analyzed by fluorescence microscopy
at a 40-fold magnification. pp , 0.05; ppp , 0.01 for comparison with
culture without ligands.
FIGURE 4. Inhibition of Treg cell function by synthetic RNA oligonu-
cleotides is mediated by APC-secreted IL-6. Teff cells were stimulated with
anti-CD3 Ab and cultured alone or together with Treg cells in the presence
of APC as in Fig. 1A. A, TLR7-deficient Teff and Treg cells were cocul-
tured with wild-type (WT) C57BL/6 APC and stimulated with 9.2dr PTO
RNA (transfected with DOTAP) or the synthetic TLR7 agonist CL097. B,
Wild-type Teff cells, Treg cells, and APC were cultured in CM either with
or without anti-IL-6 Ab. CM was generated by incubating wild-type APC
with RNA 9.2dr, CL097, or CpG for 2 h followed by extensive washing and
culture in fresh medium without additional stimulation for 24 h. C, 23 105
splenic APC were stimulated for 24 h with either 9.2dr PTO RNA (trans-
fected with DOTAP), 59-triphosphate RNA (3P-2.2, transfected with lip-
ofectamine), or Poly A PTO (transfected with DOTAP) and the levels of IL-
6 and IFN-a were determined by ELISA. Error bars indicate SEM of n = 3.
pp , 0.05; ppp , 0.01 for comparison with culture without ligands.
The Journal of Immunology 943
 at U
niversity of Zurich on Septem
ber 18, 2019
http://w
w
w
.jimmunol.org/
D
ow
nloaded from
 
of Treg cell function seemed to be most effective upon infection
with Sendai virus. Generally, viral infection led to a moderate
reduction in the overall proliferation levels that may result from
a reduction of cellularity. Flow cytometry analysis confirmed that
CD4+FoxP3neg Teff cells show sustained proliferation on viral
infection (Supplemental Fig. 4); the proliferation levels of Treg
cells remained unaffected (data not shown). Viral infection did not
lead to IL-6 production in the T cell coculture (IL-6 was not de-
tectable for both EMCV and Sendai virus), confirming T cell
purity and thus an APC-independent mechanism for the inhibition
of Treg cell function. Thus, RNA viruses can inhibit the sup-
pressive function of Treg cells even in the absence of APC.
Treg cells express the RNA-sensing receptors RIG-I and MDA-5
The direct effect of RNAviruses onTreg cell function suggested that
T cells may express RNA-sensing receptors. To analyze Treg and
Teff cells for their expression of RIG-I–like helicases CD4+CD25+
Treg cells and CD4+CD25neg Teff cells were isolated by magnetic
cell separation from the spleen of wild-type BALB/c mice and
analyzed by quantitative PCR. Interestingly, Treg and Teff cells
expressed both RIG-I and MDA-5 at levels similar to DC (Fig. 6A).
Relative to expression levels on DC, RIG-I was expressed on Treg
cells at higher levels than MDA-5. Analysis of TLRs revealed low
expression of TLR9 on both Treg and Teff cells compared with
DC, whereas TLR7 expression was low only on Teff cells. Anal-
ysis by mRNA microarray from highly pure CD4+GFPFoxP3+ and
CD4+GFPFoxP3neg cells sorted from mice expressing GFP under
the control of the FoxP3 promotor (24) confirmed the expression of
RIG-I and MDA-5 on Treg cells (Fig. 6B).
Loss of Treg cell function upon EMCV infection is mediated
through MDA-5
The virus-induced APC-independent loss of Treg cell-mediated
suppression and the presence of RNA-sensing receptors on these
cells suggests that activation of RIG-I–like helicases in Treg cells
may directly block their function. To test this hypothesis, we
purified Treg and Teff cells from wild-type and MDA-5-deficient
mice and infected the cocultures with EMCV. EMCV infection did
not alter Treg cell function in the cocultures derived from MDA-
5–deficient mice, in contrast to inhibition of Treg cell function
seen in wild-type mice (Fig. 7, top and middle panels). To in-
vestigate whether MDA-5 expression on Treg cells is required to
inhibit their suppressive function, we cocultured MDA-5–deficient
Treg cells together with wild-type Teff cells and infected the cells
with EMCV. Strikingly, the selective deficiency of MDA-5 on
Treg cells was sufficient to completely prevent the virus-induced
loss of Treg cell function (Fig. 7, lower panel). Thus, activation of
MDA-5 on Treg cells is necessary to block their suppressive
function on viral infection. Interestingly, by coculturing wild-type
Treg cells together with MDA-5–deficient Teff cells, we found
that MDA-5 expression by Teff cells is a further requirement for
the loss of Treg cell function (Supplemental Fig. 5). Thus, in-
hibition of Treg cell function by EMCV requires that both Treg
and Teff cells are simultaneously stimulated through MDA-5.
Discussion
Viral infection of the host is generally followed by the induction of
antiviral immunity. The development of an immune response is,
however, tightly controlled by Treg cells, and the mechanisms by
which Treg cell-induced suppression is overcome on viral infection
remain incompletely understood. As viral nucleic acids are potent
activators of innate immunity, we investigated the potential of RNA
ligands to inhibit Treg cell function. Interestingly, only the endosomal
delivery of PTO-modified RNA oligonucleotides with specific
immunostimulatory sequencemotifs (9.2dr, 21Uor 2.2) blockedTreg
cell-induced suppression. This effect was mediated through stimu-
lation of TLR7, as suppression was not inhibited in TLR7-deficient
mice.Cytosolic targetingofRIG-I–likehelicaseswith59-triphosphate
RNA or poly (I:C) elicited strong activation in terms of cytokine se-
cretion or upregulation of the early activation marker CD69 on DCs,
but failed to block Treg cell-induced suppression. Inhibition of Treg
cell function through TLR7 was mediated indirectly via soluble
factors produced by APC. Neutralization of IL-6 completely pre-
vented this effect, as shown previously for the bacterial ligands LPS
and CpG (4). Among the different immunostimulatory RNAs tested
in our study, the TLR7-activating RNA oligonucleotides induced
strong IL-6 production, which has been shown to require MyD88-
dependent activation of NF-kB (38, 39). Although activation of
RIG-I can also signal via NF-kB through the adaptors IFN-b pro-
moter stimulator protein 1 and TNFR-associated factor-6 (40, 41),
we show that, on stimulation of primary murine splenocytes with
triphosphate RNA, only low levels of IL-6 are produced, in contrast
to high levels of type I IFN. This may thus explain the inability of
triphosphate RNA to overcome Treg cell-induced suppression.
FIGURE 5. RNA viruses inhibit Treg cell function
independently from APC. Teff cells (7.5 3 104) were
cocultured in the presence (A) or in the absence (B) of
APC with increasing concentrations of Treg cells (1.25,
2.5, 3.75, and 53 104; no 53 104 condition forA) for 3 d.
Cocultures were stimulated with microbeads coated with
anti-CD3 and anti-CD28Ab and infectedwithEMCVand
Sendaivirus.NoAb, conditionswithoutAb-coatedbeads.
Error bars indicate SEM of n = 3. For comparison with
culturewith Teff cells alone:pp, 0.05; pppp, 0.001; no
asterisk, no significant suppression.
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Inhibition of Treg cell function is an important issue for many
clinical applications. During vaccination, any type of adjuvant
needs to bear the potential to overcome Treg cell suppression (42).
We show in this study that the immunostimulatory capacity of the
different RNAs in terms of induction of CD69 or IFN-a secretion
does not necessarily correlate with their potential to suppress Treg
cell function. In particular, transfection of DCs with triphosphate
RNA led to a potent activation of the cells, but did not alter
suppression by Treg cells. In vivo, this type of RNA has also been
proven to potently activate innate immunity (25), but its potential
as a vaccine adjuvant remains to be shown. We further demon-
strate in this study a high efficacy of synthetic PTO-modified short
immunostimulatory RNA for the reversal of Treg cell suppression.
Indeed, these TLR7-activating RNAs have been proven to be ef-
fective adjuvants for the induction of Ag-specific T and B cells
(17, 43, 44). Immunosuppression by Treg cells plays a crucial role
in the process of malignant disease, and strategies aiming to in-
hibit these cells in cancer-bearing organisms improve the effi-
ciency of immunotherapy (45, 46). Suppression of Treg cell
function increases host immunity against cancer and efficient
delivery of ligands for TLR7 or RIG-I–like helicases may thus
represent a promising therapeutic approach.
The suppressive function of Treg cells can be regulated not only
indirectly by inflammatory factors derived from APC, but also
through the direct activation of TLRs expressed on these cells
themselves (47). A semiquantitative RNA analysis of murine Treg
cells previously showed a strong expression of the TLRs 1, 2, 4,
and 7 and lower levels of TLR5 and 8 (48); expression of TLR2
was further confirmed by quantitative PCR (9). We show in this
study for the first time that Treg cells express not only TLRs but
also the cytoplasmic helicases RIG-I and MDA-5, and we confirm
these novel findings on highly purified GFPFoxP3+ cells. Liposo-
mal transfection of the cells with RNA ligands for RIG-I and
MDA-5, however, showed no significant effects on Treg cell
suppression. This may be due to a limited transfection efficacy of
primary T cells (35, 36). Indeed, we could show that liposomal
reagents failed to deliver RNA ligands to the cytosol or to the
endosome of T cells, but efficiently targeted both compartments in
DCs. An alternative method of nucleic acid delivery is the trans-
duction of cells by viruses. In this study, we used viruses known
for their specific ability to stimulate either RIG-I (Sendai virus) or
MDA-5 (EMCV). Interestingly, both viruses completely reversed
Treg cell-induced suppression even in the absence of APC and in
an IL-6–independent manner. In a previous study, transfer of su-
pernatant from DCs stimulated with inactivated Sendai virus
particles could reduce Treg cell suppression (49), indicating that
viruses could also indirectly inhibit the function of Treg cells. We
show in an APC-independent system that direct stimulation of the
RIG-I–like helicase MDA-5 on Treg cells is necessary to inhibit
their suppressive function upon viral infection. In addition, the
FIGURE 6. Treg cells express RIG-I–like helicases. A, Real-time PCR
analysis of RIG-I, MDA-5, TLR7, and TLR9 transcript patterns in CD4+
CD25+ Treg cells, CD4+CD25neg Teff cells, and CD11c+ DCs. Levels of
mRNA are represented as relative units reflecting the copies per hypoxan-
thine phosphoribosyltransferase transcript. Error bars indicate SEM of n = 3.
Comparison to DC: pp , 0.05; ppp , 0.01; no asterisk, no significant dif-
ference to DC. B, CD4+GFPFoxP3+ Treg cells and CD4+GFPFoxP3neg Teff
cells were purified frommice expressingGFP under the control of the FoxP3
promoter. The mRNA levels of both cell types were analyzed by microarray.
Bars indicate the fluorescence intensity of the respective gene transcripts.
FIGURE 7. Inhibition of Treg function on EMCV infection depends on
MDA-5 expression in Treg cells. Teff cells (7.5 3 104) from wild-type
C57BL/6 or MDA-5–deficient mice were stimulated using microbeads
coated with anti-CD3 and anti-CD28 Ab and cultured alone or together
with increasing concentrations of Treg cells (1.25 and 2.5 3 104) in the
absence of APC. Cocultures were stimulated with EMCV. No Ab, con-
ditions without Ab-coated beads. Error bars indicate SEM of n = 3. pp ,
0.05 for comparison with culture with Teff cells alone.
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simultaneous activation of MDA-5 on Teff cells is required for this
inhibition. This suggests that activation by EMCV initiates inter-
actions between Treg and Teff cells that block Treg cell-induced
suppression. In summary, RIG-I–like helicases expressed by Treg
and Teff cells play a previously unidentified role in modulating T
cell activation and may represent an important component in the
regulation of the host immune response.
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